MAPK1(丝裂原活化蛋白激酶1)是MAPK家族的重要成员,属于ERK(细胞外信号调节激酶)亚家族,也被称为ERK2。该基因编码的蛋白是一种丝氨酸/苏氨酸激酶,在细胞增殖、分化、存活和凋亡等关键生物学过程中发挥核心作用。MAPK1通常被上游的RAS-RAF-MEK信号通路激活,通过磷酸化下游靶蛋白(如转录因子、细胞骨架蛋白等)传递信号。该基因的突变或异常表达与多种疾病密切相关,尤其是癌症。例如,MAPK1的功能获得性突变可能导致信号通路持续激活,促进肿瘤发生;而功能缺失性突变则可能影响细胞正常生长和分化。MAPK1过表达常见于多种恶性肿瘤(如乳腺癌、肺癌和结直肠癌),与肿瘤侵袭性和不良预后相关;相反,其表达降低可能导致发育缺陷或免疫功能障碍。MAPK家族(包括ERK、JNK和p38等亚家族)的共性在于它们都能被不同的细胞外刺激激活,通过三级激酶级联反应转导信号,参与应激反应、炎症和细胞周期调控等过程。该基因还与阿尔茨海默病、自身免疫性疾病和心血管疾病存在关联,其抑制剂已被开发为抗癌药物(如MEK抑制剂)。研究还发现MAPK1能与其他信号通路(如PI3K-AKT)交叉作用,形成复杂的调控网络。
None
无
MAPK1基因(以及对应的蛋白质)的细胞分布位置:
MAPK1基因的本体(GO)信息:
| 名称 |
|---|
| 4014 Ras signaling pathway [PATH:hsa04014] |
| 4015 Rap1 signaling pathway [PATH:hsa04015] |
| 4010 MAPK signaling pathway [PATH:hsa04010] |
| 4012 ErbB signaling pathway [PATH:hsa04012] |
| 4350 TGF-beta signaling pathway [PATH:hsa04350] |
| 4370 VEGF signaling pathway [PATH:hsa04370] |
| 4668 TNF signaling pathway [PATH:hsa04668] |
| 4066 HIF-1 signaling pathway [PATH:hsa04066] |
| 4068 FoxO signaling pathway [PATH:hsa04068] |
| 4071 Sphingolipid signaling pathway [PATH:hsa04071] |
| 4024 cAMP signaling pathway [PATH:hsa04024] |
| 4022 cGMP - PKG signaling pathway [PATH:hsa04022] |
| 4151 PI3K-Akt signaling pathway [PATH:hsa04151] |
| 4150 mTOR signaling pathway [PATH:hsa04150] |
| 4810 Regulation of actin cytoskeleton [PATH:hsa04810] |
| 4114 Oocyte meiosis [PATH:hsa04114] |
| 4510 Focal adhesion [PATH:hsa04510] |
| 4520 Adherens junction [PATH:hsa04520] |
| 4540 Gap junction [PATH:hsa04540] |
| 4550 Signaling pathways regulating pluripotency of stem cells [PATH:hsa04550] |
| 4611 Platelet activation [PATH:hsa04611] |
| 4620 Toll-like receptor signaling pathway [PATH:hsa04620] |
| 4621 NOD-like receptor signaling pathway [PATH:hsa04621] |
| 4650 Natural killer cell mediated cytotoxicity [PATH:hsa04650] |
| 4660 T cell receptor signaling pathway [PATH:hsa04660] |
| 4662 B cell receptor signaling pathway [PATH:hsa04662] |
| 4664 Fc epsilon RI signaling pathway [PATH:hsa04664] |
| 4666 Fc gamma R-mediated phagocytosis [PATH:hsa04666] |
| 4062 Chemokine signaling pathway [PATH:hsa04062] |
| 4910 Insulin signaling pathway [PATH:hsa04910] |
| 4912 GnRH signaling pathway [PATH:hsa04912] |
| 4915 Estrogen signaling pathway [PATH:hsa04915] |
| 4914 Progesterone-mediated oocyte maturation [PATH:hsa04914] |
| 4917 Prolactin signaling pathway [PATH:hsa04917] |
| 4921 Oxytocin signaling pathway [PATH:hsa04921] |
| 4919 Thyroid hormone signaling pathway [PATH:hsa04919] |
| 4916 Melanogenesis [PATH:hsa04916] |
| 4261 Adrenergic signaling in cardiomyocytes [PATH:hsa04261] |
| 4270 Vascular smooth muscle contraction [PATH:hsa04270] |
| 4960 Aldosterone-regulated sodium reabsorption [PATH:hsa04960] |
| 4724 Glutamatergic synapse [PATH:hsa04724] |
| 4725 Cholinergic synapse [PATH:hsa04725] |
| 4726 Serotonergic synapse [PATH:hsa04726] |
| 4720 Long-term potentiation [PATH:hsa04720] |
| 4730 Long-term depression [PATH:hsa04730] |
| 4723 Retrograde endocannabinoid signaling [PATH:hsa04723] |
| 4722 Neurotrophin signaling pathway [PATH:hsa04722] |
| 4320 Dorso-ventral axis formation [PATH:hsa04320] |
| 4360 Axon guidance [PATH:hsa04360] |
| 4380 Osteoclast differentiation [PATH:hsa04380] |
| 4713 Circadian entrainment [PATH:hsa04713] |
| 5200 Pathways in cancer [PATH:hsa05200] |
| 5230 Central carbon metabolism in cancer [PATH:hsa05230] |
| 5231 Choline metabolism in cancer [PATH:hsa05231] |
| 5206 MicroRNAs in cancer [PATH:hsa05206] |
| 5205 Proteoglycans in cancer [PATH:hsa05205] |
| 5203 Viral carcinogenesis [PATH:hsa05203] |
| 5210 Colorectal cancer [PATH:hsa05210] |
| 5212 Pancreatic cancer [PATH:hsa05212] |
| 5214 Glioma [PATH:hsa05214] |
| 5216 Thyroid cancer [PATH:hsa05216] |
| 5221 Acute myeloid leukemia [PATH:hsa05221] |
| 5220 Chronic myeloid leukemia [PATH:hsa05220] |
| 5218 Melanoma [PATH:hsa05218] |
| 5211 Renal cell carcinoma [PATH:hsa05211] |
| 5219 Bladder cancer [PATH:hsa05219] |
| 5215 Prostate cancer [PATH:hsa05215] |
| 5213 Endometrial cancer [PATH:hsa05213] |
| 5223 Non-small cell lung cancer [PATH:hsa05223] |
| 5010 Alzheimer's disease [PATH:hsa05010] |
| 5020 Prion diseases [PATH:hsa05020] |
| 5034 Alcoholism [PATH:hsa05034] |
| 4930 Type II diabetes mellitus [PATH:hsa04930] |
| 5132 Salmonella infection [PATH:hsa05132] |
| 5131 Shigellosis [PATH:hsa05131] |
| 5133 Pertussis [PATH:hsa05133] |
| 5152 Tuberculosis [PATH:hsa05152] |
| 5164 Influenza A [PATH:hsa05164] |
| 5161 Hepatitis B [PATH:hsa05161] |
| 5160 Hepatitis C [PATH:hsa05160] |
| 5145 Toxoplasmosis [PATH:hsa05145] |
| 5140 Leishmaniasis [PATH:hsa05140] |
| 5142 Chagas disease (American trypanosomiasis) [PATH:hsa05142] |
| 名称 |
|---|
| Activated TLR4 signalling |
| Activation of NMDA receptor upon glutamate binding and postsynaptic events |
| Activation of the AP-1 family of transcription factors |
| Advanced glycosylation endproduct receptor signaling |
| ARMS-mediated activation |
| Axon guidance |
| Ca-dependent events |
| Cell Cycle |
| Cell Cycle, Mitotic |
| Cellular response to heat stress |
| Cellular responses to stress |
| Cellular Senescence |
| CREB phosphorylation through the activation of Ras |
| Cytokine Signaling in Immune system |
| DAP12 interactions |
| DAP12 signaling |
| Developmental Biology |
| Downstream signal transduction |
| Downstream signaling of activated FGFR1 |
| Downstream signaling of activated FGFR2 |
| Downstream signaling of activated FGFR3 |
| Downstream signaling of activated FGFR4 |
| ERK activation |
| ERK/MAPK targets |
| ERK2 activation |
| ERKs are inactivated |
| Fc epsilon receptor (FCERI) signaling |
| FCERI mediated MAPK activation |
| Fcgamma receptor (FCGR) dependent phagocytosis |
| FRS-mediated FGFR1 signaling |
| FRS-mediated FGFR2 signaling |
| FRS-mediated FGFR3 signaling |
| Frs2-mediated activation |
| FRS2-mediated FGFR4 signaling |
| G-protein mediated events |
| Gastrin-CREB signalling pathway via PKC and MAPK |
| Golgi Cisternae Pericentriolar Stack Reorganization |
| GRB2 events in EGFR signaling |
| GRB2 events in ERBB2 signaling |
| Growth hormone receptor signaling |
| Hemostasis |
| IGF1R signaling cascade |
| Immune System |
| Innate Immune System |
| Insulin receptor signalling cascade |
| Interleukin-2 signaling |
| IRS-mediated signalling |
| IRS-related events |
| IRS-related events triggered by IGF1R |
| L1CAM interactions |
| M Phase |
| MAP kinase activation in TLR cascade |
| MAPK targets/ Nuclear events mediated by MAP kinases |
| Mitotic Prophase |
| MyD88 cascade initiated on plasma membrane |
| MyD88 dependent cascade initiated on endosome |
| MyD88-independent TLR3/TLR4 cascade |
| MyD88:Mal cascade initiated on plasma membrane |
| NCAM signaling for neurite out-growth |
| Negative regulation of FGFR1 signaling |
| Negative regulation of FGFR2 signaling |
| Negative regulation of FGFR3 signaling |
| Negative regulation of FGFR4 signaling |
| Neuronal System |
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell |
| NGF signalling via TRKA from the plasma membrane |
| Nuclear Events (kinase and transcription factor activation) |
| Oncogene Induced Senescence |
| Opioid Signalling |
| Oxidative Stress Induced Senescence |
| phospho-PLA2 pathway |
| Platelet activation, signaling and aggregation |
| PLC beta mediated events |
| Post NMDA receptor activation events |
| Prolonged ERK activation events |
| RAF/MAP kinase cascade |
| Recycling pathway of L1 |
| Regulation of actin dynamics for phagocytic cup formation |
| Regulation of HSF1-mediated heat shock response |
| RHO GTPase Effectors |
| RHO GTPases Activate WASPs and WAVEs |
| RSK activation |
| Senescence-Associated Secretory Phenotype (SASP) |
| SHC-mediated signalling |
| SHC-related events |
| SHC-related events triggered by IGF1R |
| SHC1 events in EGFR signaling |
| SHC1 events in ERBB2 signaling |
| SHC1 events in ERBB4 signaling |
| Signal attenuation |
| Signal Transduction |
| Signal transduction by L1 |
| Signaling by EGFR |
| Signaling by ERBB2 |
| Signaling by ERBB4 |
| Signaling by FGFR |
| Signaling by FGFR1 |
| Signaling by FGFR2 |
| Signaling by FGFR3 |
| Signaling by FGFR4 |
| Signaling by GPCR |
| Signaling by Insulin receptor |
| Signaling by Interleukins |
| Signaling by Leptin |
| Signaling by PDGF |
| Signaling by Rho GTPases |
| Signaling by SCF-KIT |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
| Signaling by VEGF |
| Signalling by NGF |
| Signalling to ERKs |
| Signalling to p38 via RIT and RIN |
| Signalling to RAS |
| SOS-mediated signalling |
| Spry regulation of FGF signaling |
| Thrombin signalling through proteinase activated receptors (PARs) |
| Toll Like Receptor 10 (TLR10) Cascade |
| Toll Like Receptor 2 (TLR2) Cascade |
| Toll Like Receptor 3 (TLR3) Cascade |
| Toll Like Receptor 4 (TLR4) Cascade |
| Toll Like Receptor 5 (TLR5) Cascade |
| Toll Like Receptor 7/8 (TLR7/8) Cascade |
| Toll Like Receptor 9 (TLR9) Cascade |
| Toll Like Receptor TLR1:TLR2 Cascade |
| Toll Like Receptor TLR6:TLR2 Cascade |
| Toll-Like Receptors Cascades |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation |
| TRAF6 Mediated Induction of proinflammatory cytokines |
| Transmission across Chemical Synapses |
| TRIF-mediated TLR3/TLR4 signaling |
| VEGFA-VEGFR2 Pathway |
| VEGFR2 mediated cell proliferation |
| 疾病名称 | 关系值 | NofPmids | NofSnps | 来源 |
| Neoplasm Metastasis | 0.141202261 | 52 | 0 | BeFree_CTD_human_LHGDN |
| Squamous cell carcinoma | 0.137150496 | 19 | 0 | BeFree_CTD_human_LHGDN |
| ovarian neoplasm | 0.128715934 | 6 | 0 | BeFree_CTD_human_LHGDN |
| Stomach Neoplasms | 0.128173051 | 4 | 0 | CTD_human_LHGDN |
| Lung Neoplasms | 0.126534468 | 8 | 0 | BeFree_CTD_human_LHGDN |
| Multiple Sclerosis | 0.123452799 | 5 | 1 | BeFree_GAD_GWASCAT |
| Kidney Neoplasm | 0.120542884 | 2 | 0 | BeFree_CTD_human |
| Sepsis | 0.120271442 | 2 | 0 | BeFree_CTD_human |
| Cardiomyopathies | 0.120271442 | 2 | 0 | BeFree_CTD_human |
| Substance Withdrawal Syndrome | 0.12 | 1 | 0 | CTD_human |
山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼
电话: 0531-88819269
E-mail: product@genelibs.com
关注微信订阅号,实时查看信息,关注医学生物学动态。